Black Diamond Therapeutics (BDTX) Retained Earnings (2018 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Retained Earnings came in at $578.1 million in Q1 2026, up 234.26% YoY from $173.0 million in Q1 2025, and up 224.39% on a QoQ basis from -$464.7 million in Q4 2025.
Black Diamond Therapeutics (BDTX) Retained Earnings (2018 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 9 years of Retained Earnings data on file, last reported at $578.1 million in Q1 2026.
- Quarterly Retained Earnings rose 234.26% year-over-year to $578.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $578.1 million (up 234.26% YoY) and the FY2025 annual result came in at -$464.7 million, down 181.48% from the prior year.
- Retained Earnings rose to $578.1 million in Q1 2026, from -$464.7 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $578.1 million in Q1 2026 to a low of -$464.7 million in Q4 2025.
- A 5-year average of $9.4 million and a median of -$115000.0 in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings surged 2112548.15% — and 2025, when it slumped 383487.83%.
- Tracing BDTX's Retained Earnings over 5 years: stood at $452.5 million in 2022, then sank by 100.01% to -$27000.0 in 2023, then surged by 2112548.15% to $570.4 million in 2024, then plunged by 181.48% to -$464.7 million in 2025, then soared by 224.39% to $578.1 million in 2026.
- The last three Retained Earnings figures came in at $578.1 million (Q1 2026), -$464.7 million (Q4 2025), and $142000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | 579.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 579.83 Mn |
| Mar 31, 2026 | 578.10 Mn |
| Dec 31, 2025 | -464.74 Mn |
| Sep 30, 2025 | 142,000.00 |
| Jun 30, 2025 | -441.13 Mn |
| Mar 31, 2025 | -430.60 Mn |
| Dec 31, 2024 | 570.36 Mn |
| Sep 30, 2024 | 568.43 Mn |
| Jun 30, 2024 | -115,000.00 |
| Mar 31, 2024 | -435.66 Mn |
| Dec 31, 2023 | -27,000.00 |
| Sep 30, 2023 | -398.02 Mn |
| Jun 30, 2023 | -375.02 Mn |
| Mar 31, 2023 | -355.86 Mn |
| Dec 31, 2022 | 452.50 Mn |
| Sep 30, 2022 | 449.63 Mn |
| Jun 30, 2022 | -2.29 Mn |
| Mar 31, 2022 | 443.66 Mn |
| Dec 31, 2021 | 440.13 Mn |
| Sep 30, 2021 | 436.75 Mn |